GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
Haijma. Sander V SV; van Dam. P Sytze PS; de Vries. Wouter R WR; Maitimu-Smeele. Inge I; Dieguez. Carlos C; Casanueva. Felipe F FF; Koppeschaar. Hans P F HP
Key Findings
- Severely obese men produced far lower GH peaks (â13âŻÂ”g/L) and overall GH exposure after GHRHâŻ+âŻGHRPâ6 than lean controls (â53âŻÂ”g/L).
- The common diagnostic cutâoff of 15âŻÂ”g/L after the test fails in obese men, falsely suggesting severe GH deficiency.
- Elderly men showed a nonâsignificant trend toward lower GH response, while IGFBPâ3 levels were reduced in the elderly compared to controls.
Practical Outcomes
- For selfâexperimenters, obesity blunts the GHâboosting effect of GHRPâ6, so a standard dose may not give the expected surge. Relying on the 15âŻÂ”g/L threshold to judge success is misleading in obese individuals; instead, track actual GH peak values or consider higher doses or combination protocols. Elderly users may see modest reductions but generally still achieve usable GH spikes.
Summary
In this study, giving a mix of GHRH and GHRPâ6 caused a strong growthâhormone (GH) surge in lean men, but severely obese men had a much weaker response, often staying below the usual 15âŻÂ”g/L cutâoff used to label GH deficiency. Older men showed a slight drop in GH response, but it wasnât statistically clear. This means the standard GH test cutâoff isnât reliable for obese people.
Abstract
Ageing and obesity result in decreased activity of the GH/IGF-I axis and concomitant impaired GH responses to secretory stimuli. We therefore determined the validity of the GH cut-off value of 15.0 microg/l in the GH-releasing hormone (GHRH)/GH releasing peptide-6 (GHRP-6) test for the diagnosis of GH deficiency in elderly or severely obese men. We performed a combined GHRH/GHRP-6 test in ten elderly men (mean age 74 years; mean body mass index (BMI) 24.6 kg/m(2)), nine obese men (mean age 47 years; mean BMI 40.6 kg/m(2)) and seven healthy male controls (mean age 51 years, mean BMI 24.3 kg/m(2)). After assessment of fasting plasma GH, IGF-I and IGF-binding protein-3 (IGFBP-3), GHRH (100 microg) and GHRP-6 (93 microg) were given intravenously as a bolus injection. Repeated GH measurements were performed for two hours. Both peak GH levels and areas under the curve (AUC) were significantly lower in the obese than in the controls (peak 13.2 vs 53.4 microg/l, P = 0.001; AUC 707 vs 3250 microg/l x 120 min; P = 0.001). Mean GH response in the elderly was lower than in the controls (peak 35.0 microg/l; AUC 2274 microg/l x 120 min), but this was not statistically significant. In contrast, GH peak levels in seven obese men remained below the cut-off level of 15.0 microg/l associated with severe GH deficiency. All others had GH peak levels exceeding this threshold. IGFBP-3 levels were significantly lower in the elderly than in the controls (1.35 vs 2.05 mg/l, P = 0.001). Baseline GH or IGF-I did not differ significantly between groups. GH responses following GHRH/GHRP-6 administration were significantly reduced in severely obese men, but were not significantly reduced in elderly men, despite a negative trend. Our data indicate that the cut-off GH level of 15.0 microg/l after GHRH + GHRP-6 administration for the diagnosis of severe GH deficiency cannot be used in severely obese men.
Study Information
pubmed
2005
10.1530/eje.1.01887